AVXL - Anavex Life Sciences Corp.

Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL

San Diego, California--(Newsfile Corp. - October 16, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

Oct 16, 2026 09:52 AM • newsfilecorp.com (Hide legal announcements)

AVXL EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Anavex between November 26, 2025 and August 28, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Oct 16, 2026 04:58 AM • newsfilecorp.com (Hide legal announcements)

Kaplan Fox Encourages Anavex Life Sciences Corp. (AVXL) Investors to Contact the Firm Before the Deadline on November 30, 2026 for a Leadership Role

New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us.

Oct 16, 2026 03:15 AM • newsfilecorp.com (Hide legal announcements)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Oct 15, 2026 02:21 PM • newsfilecorp.com (Hide legal announcements)

Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome

Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Company may proceed with its planned clinical study under its Investigational New Drug Application (IND) for ANAVEX®2-73 (blarcamesine) for Fragile X syndrome (FXS), a genetic condition that is the most common inherited cause of intellectual disability and developmental delay and the most commonly known single-gene cause of autism, for which no FDA-approved treatment currently exists. The IND is now open, enabling clinical investigation of blarcamesine in FXS in the United States.

Oct 15, 2026 12:00 PM • globenewswire.com

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Anavex Life Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Oct 15, 2026 11:45 AM • prnewswire.com (Hide legal announcements)

Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - October 15, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period").

Oct 15, 2026 08:00 AM • newsfilecorp.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Oct 15, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Oct 14, 2026 02:16 PM • newsfilecorp.com (Hide legal announcements)

AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights

NEW YORK--(BUSINESS WIRE)---- $AVXL #ClassActionLawsuit--If you have suffered a loss on your Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until November 30, 2026 to ask the Court to appoint them as lead plaintiff.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The.

Oct 14, 2026 02:00 PM • businesswire.com (Hide legal announcements)

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Anavex between November 26, 2025 and August 28, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Oct 14, 2026 12:53 PM • newsfilecorp.com (Hide legal announcements)

ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Oct 14, 2026 11:30 AM • globenewswire.com (Hide legal announcements)

Kaplan Fox Advises Anavex Life Sciences Corp. (AVXL) Investors to Act Before the Lead Plaintiff Deadline on November 30, 2026

New York, New York--(Newsfile Corp. - October 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us.

Oct 14, 2026 09:30 AM • newsfilecorp.com (Hide legal announcements)

AVXL Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corp. Class Action Lawsuit

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

Oct 13, 2026 02:51 PM • globenewswire.com (Hide legal announcements)

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Oct 13, 2026 02:11 PM • newsfilecorp.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines – AVXL

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Oct 13, 2026 01:24 PM • globenewswire.com (Hide legal announcements)

DEADLINE ALERT for QFIN, DAVA, AVXL, GOOGL: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Oct 13, 2026 12:10 PM • globenewswire.com (Hide legal announcements)

Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Oct. 13, 2026 (GLOBE NEWSWIRE) --  Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 30, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026 inclusive (the “Class Period”).

Oct 13, 2026 11:50 AM • globenewswire.com (Hide legal announcements)

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Oct 12, 2026 02:06 PM • newsfilecorp.com (Hide legal announcements)

Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR NewswireLOS ANGELES, Oct. 12, 2026LOS ANGELES,

Oct 12, 2026 11:00 AM • gurufocus.com

Cantor Fitzgerald Downgrades Anavex Life Sciences to Neutral, Lowers Price Target to $11

$11.00 (was $8.54)

Cantor Fitzgerald

Dec 06, 2022 03:17 AM • Benzinga